Joubert M, Desbois A, Domont F, Ghembaza A, Le Joncour A, Mirouse A
J Clin Med. 2023; 12(11).
PMID: 37297843
PMC: 10253549.
DOI: 10.3390/jcm12113648.
He K, Yan X, Wu D
Int J Mol Sci. 2023; 24(9).
PMID: 37175882
PMC: 10179024.
DOI: 10.3390/ijms24098176.
Balamurugan S, Somanath A
Indian J Ophthalmol. 2022; 70(12):4361-4363.
PMID: 36453345
PMC: 9940529.
DOI: 10.4103/ijo.IJO_2123_22.
Gueudry J, Leclercq M, Saadoun D, Bodaghi B
J Clin Med. 2021; 10(11).
PMID: 34073249
PMC: 8198480.
DOI: 10.3390/jcm10112318.
Massa H, Pipis S, Adewoyin T, Vergados A, Patra S, Panos G
Clin Ophthalmol. 2019; 13:1761-1777.
PMID: 31571815
PMC: 6750710.
DOI: 10.2147/OPTH.S180580.
Update in treatment of uveitic macular edema.
Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos P
Drug Des Devel Ther. 2019; 13:667-680.
PMID: 30858697
PMC: 6387597.
DOI: 10.2147/DDDT.S166092.
Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
Park J, Chung Y, Lee K, Song J, Lee E
Yonsei Med J. 2015; 56(4):1158-62.
PMID: 26069144
PMC: 4479849.
DOI: 10.3349/ymj.2015.56.4.1158.
Review of Systemic Immunosuppression for Autoimmune Uveitis.
Castiblanco C, Foster C
Ophthalmol Ther. 2014; 3(1-2):17-36.
PMID: 25134495
PMC: 4254861.
DOI: 10.1007/s40123-014-0023-x.
[Biologics: from the "golden calf" to a "gold standard"?].
Pleyer U
Ophthalmologe. 2011; 108(3):201-3.
PMID: 21369866
DOI: 10.1007/s00347-010-2259-8.
Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease.
Zakka F, Chang P, Giuliari G, Foster C
Clin Ophthalmol. 2009; 3:567-79.
PMID: 19898629
PMC: 2770868.
DOI: 10.2147/opth.s4445.
Interferons and their potential in the treatment of ocular inflammation.
Mackensen F, Max R, Becker M
Clin Ophthalmol. 2009; 3:559-66.
PMID: 19898628
PMC: 2770867.
DOI: 10.2147/opth.s3308.
Managing Behçet's disease: An update on current and emerging treatment options.
van Daele P, Kappen J, van Hagen P, van Laar J
Ther Clin Risk Manag. 2009; 5(2):385-90.
PMID: 19536320
PMC: 2697543.
DOI: 10.2147/tcrm.s4446.
Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Le Thi Huong D
Br J Ophthalmol. 2006; 91(3):335-9.
PMID: 17050581
PMC: 1857681.
DOI: 10.1136/bjo.2006.101550.
Management of sight-threatening uveitis: new therapeutic options.
Becker M, Smith J, Max R, Fiehn C
Drugs. 2005; 65(4):497-519.
PMID: 15733012
DOI: 10.2165/00003495-200565040-00005.
Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kotter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Gunaydin I
Br J Ophthalmol. 2003; 87(4):423-31.
PMID: 12642304
PMC: 1771623.
DOI: 10.1136/bjo.87.4.423.
Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
Kotter I, Eckstein A, Stubiger N, Zierhut M
Br J Ophthalmol. 1998; 82(5):488-94.
PMID: 9713053
PMC: 1722610.
DOI: 10.1136/bjo.82.5.488.
